1. Name and Address of Reporting Person*  
Adams Timothy M  
(C/O PREVAIL THERAPEUTICS INC.  
430 EAST 29TH STREET, SUITE 1520  
NEW YORK NY 10016  
1. Name and Address of Reporting Person*  
Adams Timothy M  
(C/O PREVAIL THERAPEUTICS INC.  
430 EAST 29TH STREET, SUITE 1520  
NEW YORK NY 10016  
2. Issuer Name and Ticker or Trading Symbol  
Prevail Therapeutics Inc. [ PRVL ]  
2. Issuer Name and Ticker or Trading Symbol  
Prevail Therapeutics Inc. [ PRVL ]  
3. Date of Earliest Transaction (Month/Day/Year)  
06/17/2020  
3. Date of Earliest Transaction (Month/Day/Year)  
06/17/2020  
5. Relationship of Reporting Person(s) to Issuer  
X Director  
5. Relationship of Reporting Person(s) to Issuer  
X Director  
6. Individual or Joint/Group Filing (Check Applicable Line)  
X Form filed by One Reporting Person  
6. Individual or Joint/Group Filing (Check Applicable Line)  
X Form filed by One Reporting Person  
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  
1. Title of Security (Instr. 3)  
Stock Option (Right to Buy)  
1. Title of Security (Instr. 3)  
Stock Option (Right to Buy)  
2. Transaction Date (Month/Day/Year)  
06/17/2020  
2. Transaction Date (Month/Day/Year)  
06/17/2020  
2A. Deemed Execution Date, if any (Month/Day/Year)  
06/17/2020  
2A. Deemed Execution Date, if any (Month/Day/Year)  
06/17/2020  
3. Transaction Code (Instr. 8)  
A  
3. Transaction Code (Instr. 8)  
A  
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)  
17,000  
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)  
17,000  
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)  
17,000  
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)  
17,000  
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)  
D  
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)  
D  
7. Nature of Indirect Beneficial Ownership (Instr. 4)  
V  
7. Nature of Indirect Beneficial Ownership (Instr. 4)  
V  
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)  
1. Title of Derivative Security (Instr. 3)  
Stock Option (Right to Buy)  
1. Title of Derivative Security (Instr. 3)  
Stock Option (Right to Buy)  
2. Conversion or Exercise Price of Derivative Security  
$16.98  
2. Conversion or Exercise Price of Derivative Security  
$16.98  
3. Transaction Date (Month/Day/Year)  
06/17/2020  
3. Transaction Date (Month/Day/Year)  
06/17/2020  
3A. Deemed Execution Date, if any (Month/Day/Year)  
06/17/2020  
3A. Deemed Execution Date, if any (Month/Day/Year)  
06/17/2020  
4. Transaction Code (Instr. 8)  
A  
4. Transaction Code (Instr. 8)  
A  
5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)  
17,000  
5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)  
17,000  
6. Date Exercisable and Expiration Date (Month/Day/Year)  
06/17/2020  
6. Date Exercisable and Expiration Date (Month/Day/Year)  
06/17/2020  
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  
Common Stock 17,000  
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  
Common Stock 17,000  
8. Price of Derivative Security (Instr. 5)  
$0.00  
8. Price of Derivative Security (Instr. 5)  
$0.00  
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)  
17,000  
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)  
17,000  
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)  
D  
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)  
D  
11. Nature of Indirect Beneficial Ownership (Instr. 4)  
D  
11. Nature of Indirect Beneficial Ownership (Instr. 4)  
D  

Explanation of Responses:  
1. This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 17, 2021 and (ii) the date immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.  

Remarks:  
/s/ Alison Haggerty, Attorney-in-Fact  
06/19/2020  
** Signature of Reporting Person Date  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).  

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.